Management



Bernard Gilly, Chairman

Bernard Gilly has over 20 years of experience in the financial and pharmaceutical sectors, and as an entrepreneur. He was Vice-President R&D for 5 years at Pasteur Mérieux Connaught (now Sanofi Pasteur). Afterwards, he became the CEO of Transgene from 1992 to 2000, heading the Company's listing and raising over $120 million. He later joined Sofinnova Partners in Paris (2000-2005). In 2005, he founded and became the CEO of Fovea Pharmaceuticals. After Fovea was acquired by Sanofi in 2009, he became Executive Vice President of the Ophthalmology Division of Sanofi. Lastly, he founded Pixium Vision in 2011.

Khalid Ishaque, CEO

Khalid Ishaque has over 20 years of experience in the medical technology sector. He joined Pixium Vision in 2014 after having spent 17 years with the Boston Scientific in various commercial and business development roles, and most recently as General Manager of International Neuromodulation division commercialising Spinal Cord and Deep Brain Stimulation systems for chronic pain and movement disorders. Before joining Boston Scientific in 1997, he worked for Becton Dickinson. He received his Master in engineering from Cranfield Institute of Technology in the United Kingdom and Master in international Economics and Management from SDA Bocconi University in Italy.

Didier Laurens, Chief Financial Officer

Didier brings extensive finance and capital markets experience, most recently as Director Investor Relations, Financing and Treasury at Korian, where he also served as Interim CFO. Previously, he was Financial Analyst with Société Générale covering various sectors including healthcare, where he accompanied numerous IPO’s. He also served as marketing manager in the pharmaceutical industry. Didier holds a post-graduate of Pharmacy, and is graduated from SFAF/CIIA.

Guillaume Buc, Chief Technology Officer (CTO)

Guillaume Buc has o ver 25 years’ experience in technology development. Before joining Pixium Vision, Mr. Buc held several management positions at GE Healthcare Europe. His latest role was CTO of the GEHC interventional cardiology department. He received an engineering degree from the French Polytechnic Institute, in applied mathematics, and a degree from the Ecole Nationale Supérieure des Télécommunications / National Telecommunications School in Paris, in image processing and computer sciences.

Robert Hill, Chief Operating Officer

Robert Hill is a specialist in industrial production and quality assurance systems. He has been leading the development and manufacturing of retinal implants for 4 years, in particular with IMI. Previously, he spent 14 years with InterVascular / Datascope where he was R&D Director, and Quality and Regulatory Affairs Director. During his experience with Intervascular, Mr. Hill helped the Company obtain ISO/EN9001/13485 certification, CE mark, FDA approval and was responsible for two fault-free FDA inspections. He has also occupied several positions in which he was in charge of clinical affairs, OEM and major projects of the Company. He also brings over 10 years’ experience working with pharmaceutical and chemical companies.

Karine Chevrie, Regulatory Affairs and Quality Director

Karine Chevrie has a PhD in Biochemistry and 20 years’ experience in the field of medical devices. During her career, she was notably in charge of regulatory strategies which contributed to obtaining CE marks and FDA approvals. She also built and managed quality management systems complying to ISO 13485 and 21CFR820 US regulation. From 2006 to 2015, Karine Chevrie held the position ofRegulatory Affairs and Quality Director at EOS Imaging. Previously, she was for 7 years in charge ofmedical devices that hold abiologicalrisk at AFSSAPS (now ANSM). In that framework, she participated in several work groups at the European Commission.

Sylvie Murgo, Intellectual Property Director

Sylvie Murgo has over 20 years of experience in the field of intellectual property of pharmaceutical and biotech industries. She started her career as a patent engineer with BioMérieux in 1994 and became Director of intellectual property department of Transgene from 1997 to 2001. Subsequently she became intellectual property director of Carex, a start-up working on metabolic disorders, until 2005. After this, she was intellectual property director at Fovea Pharmaceuticals and joined Pixium Vision in 2013.